GRAIL News - Candlesense

GRAIL Reports Second Quarter 2025 Financial Results

Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be ...

What are the potential impacts on GRAIL's long‑term growth trajectory and market share in the early‑detection market? What are the competitive risks from other companies developing multi-cancer early detection tests? How might regulatory developments or reimbursement changes affect future revenue?

Earnings

26 days ago